Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Delcath Systems

This article was originally published in The Gray Sheet

Executive Summary

National Cancer Institute Phase II study of the firm's catheter-based perfusion technology to deliver the chemotherapy drug melphalan will begin "shortly" to treat primary hepatic tumors and metastatic liver cancer originating from adenocarcinoma, neuro-endocrine or melanoma cancers. Data from 18 patients in the Phase I NCI study showed that more aggressive melphalan treatment is possible using the local delivery technique. Anti-tumor activity was achieved in 75%, or six of eight subjects with inoperable metastatic liver cancers that began as ocular melanoma, Delcath says...

You may also be interested in...



Grant & Licensing Opportunities In Brief

NCI shortage will not affect grants: National Cancer Institute funding of research project grants (RPG) will increase slightly and remain at 46% ($2.2 bil.) of overall budget, despite funding deficit in fiscal 2005. Although the NIH institute technically received a 1.8% budget increase in FY 2005, NCI has $62 mil. less than FY 2004 largely due to continuing RPG obligations, the agency stresses in the Jan. 18 NCI Cancer Bulletin. Reductions will take place outside of RPGs, training, cooperative research groups and specialized programs of research excellence. NCI's Board of Scientific Advisors, Board of Scientific Counselors and National Cancer Advisory Board are discussing how best to manage the remaining funds and how to continue to support new research...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Edgewell Finds COVID Bright Side: Wet Ones On Way To Becoming ‘Little Mega-Brand’

Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel